Home / Catalogue/ Sexual health/ PT-141 (Bremelanotide)

Sexual healthIn StockSubQ injection

PT-141 (Bremelanotide)

Cyclic heptapeptide · Melanocortin receptor agonist · 7 amino acids

Half-life

~2.7h

After administration

Delivery Method

SubQ injection

Route of administration

Storage (Lyophilised)

12-24 months

room temp in foil pouch until use

Storage (Reconstituted)

4–6 weeks

Refrigerate at 2-8C

Known For

FDA-approved as Vyleesi for female hypoactive sexual desire disorder. Works centrally (brain) to increase sexual arousal and desire in both men and women. Unlike Viagra/Cialis, works on desire not just blood flow.

Mechanism of Action

Melanocortin-4 receptor agonist — acts centrally in the brain to increase sexual desire. Does NOT work on blood flow (unlike Viagra). Works on desire, not mechanics.

Body vs. External Supply

🔴 Exogenous (replaces natural)

Brand / Trade Names

Vyleesi® FDA-approved (2019) for HSDD Manufacturer: Palatin Technologies / AMAG

Typical Research Dosage

Men: 1-2mg SubQ 45-60 min before activity. Women: 1.75mg SubQ (FDA dose). Do not exceed 1 dose per 24h or 8 doses per month.

Vial Duration Guide

10mg vial at 1.75mg/dose = ~5-6 doses.

Recommended Vial Size

★ 10mg (only size) At 1.75mg per use, ~5-6 uses per vial over 3-4 weeks ✓. Good shelf life fit for regular use.

Time to Effects

EARLY: 45-60 minutes FULL: Single dose This is an ON-DEMAND peptide, not a daily protocol. 45-60 min post-injection: Increased arousal and desire. Effects peak at 1-3 hours. Duration: 6-12 hours of enhanced sexual desire/function. No loading or accumulation needed. Each injection is a standalone event. Effects felt from the very first dose in most users. Side effects (nausea, flushing, headache) also occur within 45-60 minutes.

Contraindications & Do Not Combine

⚠️ Do NOT combine with nitrates (nitroglycerin, isosorbide) — risk of severe hypotension • Do NOT exceed 1 dose per 24 hours or 8 doses per month (FDA limit) • Caution with blood pressure medications (PT-141 can transiently increase BP)

Common Side Effects

Nausea (40% — most common reason for discontinuation), flushing (20%), headache (11%), injection site reaction, transient ↑BP

Drug Interactions

Antihypertensives (additive BP effects), naltrexone (may reduce efficacy — opioid pathway interaction). Max 8 doses/month (FDA label).

Reversibility

Fully reversible — no lasting effects after clearance

Key Peer-Reviewed References

All studies are published in indexed journals unless otherwise noted.

• Kingsberg et al. (2019) Obstet Gynecol 134:899-908 — Phase 3 RECONNECT trials • FDA Approved: Vyleesi (2019) for hypoactive sexual desire disorder (HSDD) in premenopausal women • ClinicalTrials.gov: NCT02338960 • Derived from Melanotan 2 research • FDA label limit: max 8 doses/month, max 1 dose/24hr

Research Disclaimer

Almost all data is preclinical (animal or in-vitro). No large-scale randomised controlled human trials are available for most compounds on this catalogue. This information is provided for research reference only.

Storage Requirements

Vyleesi: room temp in foil pouch until use. Research: reconstituted 2-8°C, 14-21 days.

State	Condition	Duration
Lyophilised (sealed)	room temp in foil pouch until use	12-24 months
Reconstituted	2-8C	4–6 weeks

Reconstitution Note

Reconstitute with bacteriostatic water (BAC water). Do not shake vigorously -- swirl gently to dissolve. Inject BAC water slowly down the side of the vial to avoid denaturing the peptide.

Video Resources

PT-141 (Bremelanotide) discussed by researchers & practitioners

Independent educational content from researchers, clinicians, and science communicators. Not affiliated with Pepnerd — provided as supplementary reading.

Educational resources only. The videos above are independent third-party content from researchers, clinicians, and science communicators. Pepnerd is not affiliated with any of these creators and does not endorse or make any claims based on their content. All products are sold strictly for in-vitro scientific research.

Select Vial Size

$70.00 per vial

Submit Your Test Results →

Quick Reference

Half-life	~2.7 hours
Delivery	SubQ injection
Typical dose	1-2mg
Storage (lyoph.)	room temp in foil pouch until use
Storage (recon.)	4–6 weeks
Endogenous?	Exogenous (replaces natural)
Suppression	None
WADA	Not listed
FDA status	Approved (Vyleesi)